Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05267886 · ClinicalTrials.gov registry record · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
A Phase 4 study of Shock, Cardiogenic, sponsored by Ottawa Heart Institute Research Corporation.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 346
- Enrollment target
- 3
- Study locations
NCT05267886 is a Phase 4 study of Shock, Cardiogenic that is actively recruiting participants, run by Ottawa Heart Institute Research Corporation. The registered enrollment target is 346 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT05267886, a Phase 4 study of Shock, Cardiogenic, is actively recruiting participants, sponsored by Ottawa Heart Institute Research Corporation.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 346 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG Dobutamine
- DRUG Milrinone
Study Locations (3)
Ontario
- Hamilton Health Sciences - Hamilton
- University of Ottawa Heart Institute - Ottawa
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2022-03-05 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05267886
The ClinicalTrials.gov registry entry for NCT05267886 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ottawa Heart Institute Research Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Shock, Cardiogenic appearing as the primary indexed condition, and to 3 interventions - of which Normal Saline is the first listed.
NCT05267886 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ontario, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05267886 about?
NCT05267886 is a clinical study titled "CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock". The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will c...
What is the current status of trial NCT05267886?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 346 participants. The study started on 2022-03-05. Estimated completion is 2026-12.
What conditions does trial NCT05267886 study?
This clinical trial studies the following conditions: Shock, Cardiogenic.
What interventions are being tested in trial NCT05267886?
The interventions under investigation include: Normal Saline (DRUG), Dobutamine (DRUG), Milrinone (DRUG).
Who is sponsoring clinical trial NCT05267886?
This trial is sponsored by Ottawa Heart Institute Research Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05267886 being conducted?
This trial has 3 study locations across Minnesota, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.